3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $100M | -$73M | 55.4% | -71.5% | -$56M | — | $32M |
| 2024 | $65M | -$55M | 55.1% | -69.5% | -$52M | — | $30M |
| 2023 | $12M | -$44M | 52.6% | -298.9% | -$33M | — | $27M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $28M | -$22M | 59.5% | -87.9% | -$25M | — | $30M |
| Dec '25 | $32M | -$13M | 59.0% | -50.2% | -$11M | — | $32M |
| Sep '25 | $27M | -$14M | 55.5% | -62.5% | -$10M | — | $38M |
| Jun '25 | $23M | -$17M | 53.8% | -85.5% | -$15M | — | $35M |
| Mar '25 | $18M | -$29M | 50.9% | -105.7% | -$20M | — | $42M |
| Dec '24 | $20M | -$18M | 57.2% | -63.8% | -$15M | — | $30M |
| Sep '24 | $17M | -$10M | 53.4% | -65.7% | -$12M | — | $17M |
| Jun '24 | $15M | -$14M | 53.7% | -78.3% | -$13M | — | $13M |
| Mar '24 | $13M | -$12M | 55.7% | -73.1% | -$13M | — | $22M |
How the market has priced BBNX against its own fundamentals since 2025-01 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 2 years, Beta Bionics, Inc.'s revenue has grown 189.1% per year. These are computed facts, not advice.
As of FY2025, Beta Bionics, Inc. reported — of total debt against $32M of cash.
In FY2025, gross margin was 55.4%, operating margin -71.5%, and net margin -73.0%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.